A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia.

Trial Profile

A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2014

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE-US
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 20 Oct 2014 Results of a post-hoc analysis of trials NCT00705783 and NCT00706654 were presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 12 Feb 2014 Results from this trial contributed to the approval of once-monthly intramuscular aripiprazole in Canada based on information reported in an Otsuka Pharmaceutical and H. Lundbeck A/S media release.
    • 28 Feb 2013 Once-monthly aripiprazole extended-release (Abilify Maintena) was approved by the US FDA as a treatment for schizophrenia based on results from this trial according to an H. Lundbeck A/S media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top